Patents Assigned to NMD PHARMA A/S
  • COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
    Publication number: 20260199369
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 5, 2023
    Publication date: July 16, 2026
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Nicholas Michael KELLY, Neerja SARASWAT, Richard J. HAMLYN
  • Compounds for the Treatment of Neuromuscular Disorders
    Publication number: 20260199273
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 5, 2023
    Publication date: July 16, 2026
    Applicant: NMD PHARMA A/S
    Inventors: Nicholas Michael KELLY, Lars J.S. KNUTSEN, Neerja SARASWAT, Richard J. HAMLYN, Farman ULLAH, Dastagiri DUDEKULA, Penchal NANDALURU, Rajesh KUMAR
  • COMPOSITIONS AND METHODS FOR TREATING MYASTHENIA GRAVIS
    Publication number: 20260102377
    Abstract: Disclosed herein are methods of treatment for myasthenia gravis (MG) that involve administering (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid, or a pharmaceutical composition thereof, to a patient suffering from symptoms of MG. Pharmaceutical compositions and kits-to-parts including (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid are also disclosed.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 16, 2026
    Applicant: NMD PHARMA A/S
    Inventors: Thomas Holm PEDERSEN, John Blundell HUTCHISON, Ole Baekgaard NIELSEN, Lars J.S. KNUTSEN, Lars NORDHOLM, Nicholas Michael KELLY, Eva Rose CHIN, Klaus Gjervig JENSEN, Peter FLAGSTAD, Jane Mary BOLD, Thomas Skjaerlund GRØNNEBAEK, Jorge Armando Quiroz BASTIAS
  • COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
    Publication number: 20260007639
    Abstract: A compound suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade is provided. The compound can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: September 16, 2025
    Publication date: January 8, 2026
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Nicholas M. KELLY, Thomas Holm PEDERSEN, Martin E. COOPER, Andrew W. BROWN
  • Compounds for the Treatment of Neuromuscular Disorders
    Publication number: 20260007625
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: September 15, 2023
    Publication date: January 8, 2026
    Applicant: NMD PHARMA A/S
    Inventors: Thomas Holm PEDERSEN, Lars J.S. KNUTSEN, Nicholas Michael KELLY, Farman ULLAH, Neerja SARASWAT, Rajesh KUMAR
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 12440477
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: October 14, 2025
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Martin E. Cooper, Andrew W. Brown
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 12415771
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: September 16, 2025
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Nicholas Kelly, Martin Brandhøj Skov, Anders Riisager, Neerja Saraswat
  • Process for the preparation of CIC-1 chloride channel inhibitors
    Patent number: 12221425
    Abstract: This disclosure relates to an improved chemical process for making compounds which are CIC-1 chloride channel inhibitors.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: February 11, 2025
    Assignee: NMD PHARMA A/S
    Inventors: Nicholas Kelly, Michael John McKenzie
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 12168643
    Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 17, 2024
    Assignee: NMD PHARMA A/S
    Inventors: Nicholas Kelly, Lars J.S. Knutsen, Daniel Paul Cotton
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11730714
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: August 22, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Lars J. S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11591284
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 28, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
    Publication number: 20220388938
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 8, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Nicholas KELLY, Martin Brandhøj SKOV, Anders RIISAGER, Neerja SARASWAT
  • COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
    Publication number: 20220306564
    Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 29, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Nicholas KELLY, Lars J.S. KNUTSEN, Daniel Paul COTTON
  • PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS
    Publication number: 20220298124
    Abstract: This disclosure relates to an improved chemical process for making compounds which are CIC-1 chloride channel inhibitors.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 22, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Nicholas KELLY, Michael John MCKENZIE
  • 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS
    Publication number: 20220274938
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 1, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Martin BROCH-LIPS, Martin E COOPER, Marc LABELLE, Thomas Holm PEDERSEN, Dastagiri DUDEKULA, Neerja SARASWAT, Rafiq A TAJ
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11147788
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 19, 2021
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Martin Broch-Lipps, Claus Elsborg Olesen, Marc Labelle, Ole Baekgaard Nielsen
  • Compounds for use in treating neuromuscular disorders
    Patent number: 10934244
    Abstract: The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: March 2, 2021
    Assignee: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 10385028
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 20, 2019
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Martin E. Cooper, Andrew W. Brown
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183863
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Martin E. Cooper, Andrew W. Brown
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183812
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj